select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Chlamydia Infections-Pipeline Review, H2 2015

Chlamydia Infections-Pipeline Review, H2 2015


  • Products Id :- GMDHC7239IDB
  • |
  • Pages: 84
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Chlamydia Infections-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chlamydia Infections-Pipeline Review, H2 2015', provides an overview of the Chlamydia Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chlamydia Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chlamydia Infections Overview 9

Therapeutics Development 10

Pipeline Products for Chlamydia Infections-Overview 10

Pipeline Products for Chlamydia Infections-Comparative Analysis 11

Chlamydia Infections-Therapeutics under Development by Companies 12

Chlamydia Infections-Therapeutics under Investigation by Universities/Institutes 14

Chlamydia Infections-Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Chlamydia Infections-Products under Development by Companies 17

Chlamydia Infections-Products under Investigation by Universities/Institutes 18

Chlamydia Infections-Companies Involved in Therapeutics Development 19

Abera Bioscience AB 19

Adamis Pharmaceuticals Corporation 20

Big DNA Ltd. 21

CEL-SCI Corporation 22

Folia Biotech Inc. 23

Genocea Biosciences, Inc. 24

Merck & Co., Inc. 25

Osel Inc. 26

Prokarium Limited 27

QureTech Bio AB 28

Selecta Biosciences, Inc. 29

SIGA Technologies, Inc. 30

Chlamydia Infections-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

Ab-03-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

acALY-18-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BDNA-003-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Biologic for Infectious Disease-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

C-31G-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

CEL-1000-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

chlamydia trachomatis vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

chlamydia vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

chlamydia vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

chlamydia vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

chlamydia vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

chlamydia vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

chlamydia vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

chlamydia vaccines-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Drugs to Block Virulence for Chlamydia Infections-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

GEN-001-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Peptides to Inhibit CPAF for Chlamydia Infections-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules for Chlamydophila Infections-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

solithromycin-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

ST-669-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

VNI-201-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Chlamydia Infections-Recent Pipeline Updates 67

Chlamydia Infections-Dormant Projects 77

Chlamydia Infections-Product Development Milestones 78

Featured News & Press Releases 78

Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology 78

Aug 03, 2015: New vaccine for Chlamydia to use synthetic biology 78

Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia 79

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 80

Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria 80

Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center 81

Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified 82

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

Number of Products under Development for Chlamydia Infections, H2 2015 10

Number of Products under Development for Chlamydia Infections-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Products under Investigation by Universities/Institutes, H2 2015 18

Chlamydia Infections-Pipeline by Abera Bioscience AB, H2 2015 19

Chlamydia Infections-Pipeline by Adamis Pharmaceuticals Corporation, H2 2015 20

Chlamydia Infections-Pipeline by Big DNA Ltd., H2 2015 21

Chlamydia Infections-Pipeline by CEL-SCI Corporation, H2 2015 22

Chlamydia Infections-Pipeline by Folia Biotech Inc., H2 2015 23

Chlamydia Infections-Pipeline by Genocea Biosciences, Inc., H2 2015 24

Chlamydia Infections-Pipeline by Merck & Co., Inc., H2 2015 25

Chlamydia Infections-Pipeline by Osel Inc., H2 2015 26

Chlamydia Infections-Pipeline by Prokarium Limited, H2 2015 27

Chlamydia Infections-Pipeline by QureTech Bio AB, H2 2015 28

Chlamydia Infections-Pipeline by Selecta Biosciences, Inc., H2 2015 29

Chlamydia Infections-Pipeline by SIGA Technologies, Inc., H2 2015 30

Assessment by Monotherapy Products, H2 2015 31

Number of Products by Stage and Target, H2 2015 33

Number of Products by Stage and Mechanism of Action, H2 2015 35

Number of Products by Stage and Route of Administration, H2 2015 37

Number of Products by Stage and Molecule Type, H2 2015 39

Chlamydia Infections Therapeutics-Recent Pipeline Updates, H2 2015 67

Chlamydia Infections-Dormant Projects, H2 2015 77

List of Figures

Number of Products under Development for Chlamydia Infections, H2 2015 10

Number of Products under Development for Chlamydia Infections-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Early Stage Products, H2 2015 16

Assessment by Monotherapy Products, H2 2015 31

Number of Products by Targets, H2 2015 32

Number of Products by Stage and Targets, H2 2015 32

Number of Products by Mechanism of Actions, H2 2015 34

Number of Products by Stage and Mechanism of Actions, H2 2015 34

Number of Products by Routes of Administration, H2 2015 36

Number of Products by Stage and Routes of Administration, H2 2015 36

Number of Products by Molecule Types, H2 2015 38

Number of Products by Stage and Molecule Types, H2 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abera Bioscience AB

Adamis Pharmaceuticals Corporation

Big DNA Ltd.

CEL-SCI Corporation

Folia Biotech Inc.

Genocea Biosciences, Inc.

Merck & Co., Inc.

Osel Inc.

Prokarium Limited

QureTech Bio AB

Selecta Biosciences, Inc.

SIGA Technologies, Inc.

Chlamydia Infections Therapeutic Products under Development, Key Players in Chlamydia Infections Therapeutics, Chlamydia Infections Pipeline Overview, Chlamydia Infections Pipeline, Chlamydia Infections Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com